Evaluating Different Doses of Orelabrutinib in MCL
Status:
Recruiting
Trial end date:
2025-05-25
Target enrollment:
Participant gender:
Summary
This is A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses
of Orelabrutinib in Mantle Cell Lymphoma to Evaluate the Efficacy and Safety in Mantle Cell
Lymphoma.